Gilead Sciences, Inc. $GILD Shares Sold by Stone Summit Wealth LLC

Stone Summit Wealth LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,189 shares of the biopharmaceutical company’s stock after selling 3,480 shares during the quarter. Stone Summit Wealth LLC’s holdings in Gilead Sciences were worth $4,053,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. XY Planning Network Inc. bought a new position in shares of Gilead Sciences in the third quarter valued at about $201,000. Salem Investment Counselors Inc. lifted its stake in shares of Gilead Sciences by 18.2% during the 3rd quarter. Salem Investment Counselors Inc. now owns 1,642 shares of the biopharmaceutical company’s stock worth $245,000 after buying an additional 253 shares during the last quarter. Signal Advisors Wealth LLC boosted its holdings in shares of Gilead Sciences by 69.9% during the 3rd quarter. Signal Advisors Wealth LLC now owns 4,675 shares of the biopharmaceutical company’s stock worth $697,000 after buying an additional 1,923 shares during the period. Copeland Capital Management LLC bought a new stake in shares of Gilead Sciences during the 3rd quarter worth about $894,000. Finally, Foster Group Inc. boosted its holdings in shares of Gilead Sciences by 8.5% during the 3rd quarter. Foster Group Inc. now owns 2,377 shares of the biopharmaceutical company’s stock worth $354,000 after buying an additional 187 shares during the period. 83.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on GILD shares. Bank of America reiterated a “buy” rating and issued a $164.00 price target on shares of Gilead Sciences in a research note on Monday. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price objective on shares of Gilead Sciences in a research report on Thursday, October 8th. Royal Bank Of Canada boosted their price objective on Gilead Sciences from $123.00 to $126.00 and gave the stock a “sector perform” rating in a report on Thursday, October 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research report on Wednesday, August 5th. Finally, HSBC increased their target price on Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $159.33.

Gilead Sciences Trading Down 1.7%

Shares of Gilead Sciences stock opened at $147.92 on Wednesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The firm has a 50-day moving average of $145.77 and a 200-day moving average of $136.87. Gilead Sciences, Inc. has a 52-week low of $114.02 and a 52-week high of $157.29. The stock has a market cap of $183.41 billion, a PE ratio of -55.40 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same quarter in the previous year, the company earned $2.01 EPS. The business’s revenue was up 10.6% on a year-over-year basis. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post -0.47 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date was Tuesday, September 15th. Gilead Sciences’s payout ratio is currently -122.85%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts remain bullish on Gilead, highlighting the company among attractive healthcare stocks. The positive view reflects Gilead’s HIV, liver-disease and oncology franchises, as well as its longer-term growth prospects. Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Gilead Sciences (GILD)
• Positive Sentiment: Bank of America said survey results support a favorable long-term outlook for Yeztugo, Gilead’s HIV-prevention drug. Strong adoption potential could provide an additional growth driver for the company’s HIV portfolio. Gilead Sciences’ Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says
• Positive Sentiment: Erste Group Bank modestly raised its FY2027 EPS forecast for Gilead to $9.90 from $9.88, signaling confidence in the company’s future profitability. Erste Group Bank Raises Gilead Sciences EPS Estimate
• Neutral Sentiment: Recent comparisons with GRAIL and Vertex Pharmaceuticals provide valuation and operating-context analysis but do not identify a specific new catalyst for GILD. Contrasting GRAIL and Gilead Sciences Gilead Sciences versus Vertex Pharmaceuticals
• Negative Sentiment: Gilead’s upcoming third-quarter earnings report is expected to show a double-digit year-over-year EPS decline. That forecast is weighing on sentiment despite optimism about the company’s longer-term pipeline and product growth. Earnings Preview: What to Expect From Gilead Sciences’ Report

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $144.22, for a total value of $432,660.00. Following the transaction, the insider owned 116,684 shares in the company, valued at $16,828,166.48. The trade was a 2.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $145.29, for a total value of $435,870.00. Following the transaction, the chief financial officer directly owned 164,096 shares of the company’s stock, valued at approximately $23,841,507.84. The trade was a 1.80% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 105,000 shares of company stock valued at $14,940,540. Corporate insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.